SCHEMBL2866936

SCHEMBL2866936

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccccc4)nc3c3cc(OC)ccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MAPT P10636 3/20 0.52
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
P2RX4 Q99571 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
PLA2G2A P14555 8/20 0.44
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PLA2G1B P04054 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868756 0.94 KMT2A (0.48) KMT2AMAPTTSHRMAPK1P2RX4
SCHEMBL2861360 0.89 P2RX4 (0.50) KMT2AMAPTMAPK1P2RX4SMN1; SMN2
SCHEMBL2871092 0.89 P2RX4 (0.54) KMT2AMAPTTSHRMAPK1P2RX4
SCHEMBL2868482 0.85 P2RX4 (0.50) KMT2AMAPTMAPK1P2RX4SMN1; SMN2
SCHEMBL2865409 0.85 KDM4E (0.41) KMT2AMAPTTSHRP2RX4SMN1; SMN2
SCHEMBL2860000 0.84 MAPT (0.49) KMT2AMAPTTSHRMAPK1P2RX4
SCHEMBL2860059 0.84 PIK3R1 (0.44) KMT2AMAPTALDH1A1HTTMEN1
SCHEMBL2867302 0.84 P2RX4 (0.48) KMT2AMAPTMAPK1P2RX4SMN1; SMN2
SCHEMBL13067134 0.83 HPGD (0.46) KMT2AMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL2859032 0.83 P2RX4 (0.46) KMT2AMAPTMAPK1P2RX4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KMT2A 1037/4885MAPT 4583/4885TSHR 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.